Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.C. Pearson, G.R. May, G.H. Fick, L.R. Sutherland.
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Ann Intern Med, 123 (1995), pp. 132-142
[2.]
W. Sandborn, L. Sutherland, D. Pearson, G. May, R. Modigliani, C. Prantera.
Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease (Cochrane review). En: The Cochrane Library, Issue 2,.
[3.]
S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig, R. Goodman.
A controlled double blind study of azathioprine in the management of Crohn's disease.
Gut, 37 (1995), pp. 674-678
[4.]
K. Ewe, A.G. Press, C.C. Singe, M. Stufler, B. Ueberschaer, G. Hommel, et al.
Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease [see comments].
Gastroenterology, 105 (1993), pp. 367-372
[5.]
M. Klein, H.J. Binder, M. Mitchell, R. Aaronson, H. Spiro.
Treatment of Crohn's disease with azathioprine: a controlled evaluation.
Gastroenterology, 66 (1974), pp. 916-922
[6.]
R. Oren, M. Moshkowitz, S. Odes, S. Becker, D. Keter, I. Pomeranz, et al.
Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial.
Am J Gastroenterol, 92 (1997), pp. 2203-2209
[7.]
D.H. Present, B.I. Korelitz, N. Wisch, J.L. Glass, D.B. Sachar, B.S. Pasternack.
Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study.
N Engl J Med, 302 (1980), pp. 981-987
[8.]
J. Rhodes, D. Bainton, P. Beck, H. Campbell.
Controlled trial of azathioprine in Crohn's disease.
Lancet, 2 (1971), pp. 1273-1276
[9.]
R.W. Summers, D.M. Switz, J.T. Sessions Jr, J.M. Becktel, W.R. Best, F. Kern Jr, et al.
National Cooperative Crohn's Disease Study: results of drug treatment.
Gastroenterology, 77 (1979), pp. 847-869
[10.]
J.M. Willoughby, J. Beckett, P.J. Kumar, A.M. Dawson.
Controlled trial of azathioprine in Crohn's disease.
Lancet, 2 (1971), pp. 944-947
[11.]
J. Hinojosa.
Anticuerpos anti-TNF en el tratamiento de la enfermedad inflamatoria intestinal.
Gastroenterol Hepatol, 23 (2000), pp. 250-257
[12.]
D.P. Jewell, S.C. Truelove.
Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.
BMJ, 4 (1974), pp. 627-630
[13.]
R. Caprilli, R. Carratu, M. Babbini.
A double-blind comparison of the effectiveness of azathioprine and sulfasalzine in idiopathic proctocolitis. Preliminary report.
Dig Dis, 20 (1975), pp. 115-120
[14.]
A. Sood, V. Midha, N. Sood, V. Kaushal.
Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial.
Indian J Gastroenterol, 19 (2000), pp. 14-16
[15.]
J. Mate-Jiménez, C. Hermida, J. Cantero-Perona, R. Moreno-Otero.
6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease.
Eur J Gastroenterol Hepatol, 12 (2000), pp. 1227-1233
[16.]
J. George, D.H. Present, R. Pou, C. Bodian, P.H. Rubin.
The longterm outcome of ulcerative colitis treated with 6-mercaptopurine.
Am J Gastroenterol, 91 (1996), pp. 1711-1714
[17.]
Z.H. Khan, J.F. Mayberry, N. Spiers, A.C. Wicks.
Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience.
Digestion, 62 (2000), pp. 249-254
[18.]
D.C. Pearson, G.R. May, G. Fick, L.R. Sutherland.
Azathioprine for maintaining remission of Crohn's disease. En: The Cochrane Library, Issue 2, 2001.
[19.]
D.P. O'Donoghue, A.M. Dawson, J. Powell-Tuck, R.L. Bown, J.E. Lennard-Jones.
Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease.
Lancet, 2 (1978), pp. 955-957
[20.]
J.L. Rosenberg, B. Levin, A.J. Wall, J.B. Kirsner.
A controlled trial of azathioprine in Crohn's disease.
Am J Dig Dis, 20 (1975), pp. 721-726
[21.]
A.H. Steinhart, K. Ewe, A.M. Griffiths, R. Modigliani, O.O. Thomsen.
Corticosteroids for maintaining remission of Crohn's disease. En: The Cochrane Library, Issue 2.
[22.]
Y. Bouhnik, M. Lemann, J.Y. Mary, G. Scemama, R. Tai, C. Matuchansky, et al.
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
Lancet, 347 (1996), pp. 215-219
[23.]
A.B. Hawthorne, R.F. Logan, C.J. Hawkey, P.N. Foster, A.T. Axon, E.T. Swarbrick, et al.
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.
BMJ, 305 (1992), pp. 20-22
[24.]
J.L. Rosenberg, A.J. Wall, B. Levin, H.J. Binder, J.B. Kirsner.
A controlled trial of azathioprine in the management of chronic ulcerative colitis.
Gastroenterology, 69 (1975), pp. 96-99
[25.]
A.P. Kirk, J.E. Lennard-Jones.
Controlled trial of azathioprine in chronic ulcerative colitis.
BMJ (Clin Res Ed), 284 (1982), pp. 1291-1292
[26.]
F. Fernández-Banares, X. Bertran, M. Esteve-Comas, E. Cabre, M. Menacho, P. Humbert, et al.
Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis.
Am J Gastroenterol, 91 (1996), pp. 2498-2499
[27.]
C.B. Lamers, G. Griffioen, R.A. Van Hogezand, R.A. Veenendaal.
Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease.
Scand J Gastroenterol Suppl, 230 (1999), pp. 111-115
[28.]
J.P. Gisbert, F. Gomollon, J. Mate, J.M. Pajares.
Tratamiento farmacológico de las fístulas en la enfermedad de Crohn.
Med Clin (Barc), 116 (2001), pp. 664-671
[29.]
C.H. Brown, E. Achkar.
Azathioprine therapy for inflammatory bowel disease. A preliminary report.
Am J Gastroenterol, 54 (1970), pp. 363-377
[30.]
B.I. Korelitz, D.H. Present.
Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease.
Dig Dis Sci, 30 (1985), pp. 58-64
[31.]
W.R. Drucker, K.N. Jeejeebhoy.
Azathioprine: an adjunct to surgical therapy of granulomatous enteritis.
Ann Surg, 172 (1970), pp. 618-626
[32.]
B.N. Brooke, S.L. Javett, O.W. Davison.
Further experience with azathioprine for Crohn's disease.
Lancet, 2 (1970), pp. 1050-1053
[33.]
J.J. O'Brien, T.M. Bayless, J.A. Bayless.
Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease [see comments].
Gastroenterology, 101 (1991), pp. 39-46
[34.]
L.S. Pichney, G.T. Fantry, S.M. Graham.
Gastrocolic and duodenocolic fistulas in Crohn's disease.
J Clin Gastroenterol, 15 (1992), pp. 205-211
[35.]
A.J. Greenstein, D.H. Present, D.B. Sachar, G. Slater, T. Heimann, P. Lachman, et al.
Gastric fistulas in Crohn's disease. Report of cases.
Dis Colon Rectum, 32 (1989), pp. 888-892
[36.]
M.L. Margolin, B.I. Korelitz.
Management of bladder fistulas in Crohn's disease.
J Clin Gastroenterol, 11 (1989), pp. 399-402
[37.]
R.E. Glass, J.K. Ritchie, J.E. Lennard-Jones, P.R. Hawley, I.P. Todd.
Internal fistulas in Crohn's disease.
Dis Colon Rectum, 28 (1985), pp. 557-561
[38.]
G. D'Haens, K. Geboes, E. Ponette, F. Penninckx, P. Rutgeerts.
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.
Gastroenterology, 112 (1997), pp. 1475-1481
[39.]
B. Korelitz, S. Hanauer, P. Rutgeerts.
Post-operative prophylaxis with 6-mercaptopurine, 5-ASA or placebo in Crohn's disease: a 2 year multicenter trial.
Gastroenterology, 114 (1998), pp. A486
[40.]
P. Nos, J. Hinojosa, V. Aguilera, J.R. Moles, M. Pastor, J. Ponce, et al.
Azatioprina y 5-ASA en la prevención de la recurrencia posquirúrgica de la enfermedad de Crohn.
Gastroenterol Hepatol, 23 (2000), pp. 374-378
[41.]
H.A. Kader, S.C. Raynor, R. Young, S.S. Kaufman, J. Vanderhoof, E.I. Ruby, et al.
Introduction of 6-mercaptopurine in Crohn's disease patients during the perioperative period: a preliminary evaluation of recurrence of disease.
J Pediatr Gastroenterol Nutr, 25 (1997), pp. 93-97
[42.]
J. Markowitz, K. Grancher, N. Kohn, M. Lesser, F. Daum.
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.
Gastroenterology, 119 (2000), pp. 895-902
[43.]
E.G. Seidman.
6-mercaptopurine in maintaining remission in Crohn's disease: An old friend becomes a new hero.
Gastroenterology, 119 (2000), pp. 1158-1160
[44.]
J. Markowitz, K. Grancher, F. Mandel, F. Daum.
Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Am J Gastroenterol, 88 (1993), pp. 44-48
[45.]
J. Markowitz, J. Rosa, K. Grancher, H. Aiges, F. Daum.
Longterm 6-mercaptopurine treatment in adolescents with Crohn's disease.
Gastroenterology, 99 (1990), pp. 1347-1351
[46.]
M. Verhave, H.S. Winter, R.J. Grand.
Azathioprine in the treatment of children with inflammatory bowel disease.
J Pediatr, 117 (1990), pp. 809-814
[47.]
M.D. Shah, W.F. Berman.
Use of azathioprine in nine children with Crohn's disease.
Va Med Q, 118 (1991), pp. 169-170
[48.]
J. Perrault, J.L. Greseth, W.J. Tremaine.
6-mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease.
Mayo Clin Proc, 66 (1991), pp. 480-484
[49.]
W.C. Jeshion, K.L. Larsen, A.F. Jawad, D.A. Piccoli, R. Verma, E.S. Maller, et al.
Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children.
J Clin Gastroenterol, 30 (2000), pp. 294-298
[50.]
B.S. Kirschner.
Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease.
Gastroenterology, 115 (1998), pp. 813-821
[51.]
W.J. Sandborn.
Rational dosing of azathioprine and 6-mercaptopurine.
Gut, 48 (2001), pp. 591-592
[52.]
P.A.L. Bonis, R.P. MacDermot.
Immunomodulator therapy in Crohn's disease.
UpToDate version 9.2, (2001), pp. 1-8
[53.]
O.H. Nielsen, B. Vainer, J. Rask-Madsen.
Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.
Aliment Pharmacol Ther, 14 (2001), pp. 1699-1708
[54.]
W.J. Sandborn.
A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
Am J Gastroenterol, 91 (1996), pp. 423-433
[55.]
W.J. Sandborn.
Azathioprine: state of the art in inflammatory bowel disease.
Scand J Gastroenterol Suppl, 225 (1998), pp. 92-99
[56.]
A. García Sánchez, M. Escudero Roldán, J.L. Pérez Calle, V. González Lara.
Utilización en el año 2000 de la azatioprina y 6-mercaptopurina en el manejo de la enfermedad inflamatoria intestinal.
Tratamiento médico en el año 2000. Enfermedad inflamatoria intestinal, pp. 113-140
[57.]
G. Decaux, F. Prospert, Y. Horsmans, J.P. Desager.
Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine.
J Lab Clin Med, 135 (2000), pp. 256-262
[58.]
T. Colonna, B.I. Korelitz.
The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease.
Am J Gastroenterol, 89 (1994), pp. 362-366
[59.]
J. Belaiche, J.P. Desager, Y. Horsmans, E. Louis.
Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Scand J Gastroenterol, 36 (2001), pp. 71-76
[60.]
M.C. Dubinsky, S. Lamothe, H.Y. Yang, S.R. Targan, D. Sinnett, Y. Theoret, et al.
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
Gastroenterology, 118 (2000), pp. 705-713
[61.]
J. Markowitz, K. Grancher, F. Mandel, F. Daum.
Relationship of leukopenia to 6-MP induced remission of Crohn's disease.
J Pediatr Gastroenterol Nutr, 27 (1998), pp. A8
[62.]
W.J. Sandborn, W.J. Tremaine, D.C. Wolf, S.R. Targan, C.A. Sninsky, L.R. Sutherland, et al.
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
Gastroenterology, 117 (1999), pp. 527-535
[63.]
Gisbert JP, Gomollón F, Maté J, Pajares JM. Terapia individualizada con azatioprina o 6-mercaptopurina mediante monitorización de la actividad de la tiopurina metiltransferasa (TPMT) [en prensa]. Rev Clin Esp.
[64.]
D.M. Tidd, A.R. Paterson.
A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine.
Cancer Res, 34 (1974), pp. 738-746
[65.]
L. Lennard, C.B. Brown, M. Fox, J.L. Maddocks.
Azathioprine metabolism in kidney transplant recipients.
Br J Clin Pharmacol, 18 (1984), pp. 693-700
[66.]
L. Lennard.
Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells.
J Chromatogr, 423 (1987), pp. 169-178
[67.]
L. Lennard, J.S. Lilleyman.
Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.
J Clin Oncol, 7 (1989), pp. 1816-1823
[68.]
C. Cuffari, Y. Theoret, S. Latour, G. Seidman.
6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
Gut, 39 (1996), pp. 401-406
[69.]
C. Cuffari, S. Hunt, T. Bayless.
Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
Gut, 48 (2001), pp. 642-646
[70.]
J.S. Lilleyman, L. Lennard.
Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.
Lancet, 343 (1994), pp. 1188-1190
[71.]
S. Bergan, H.E. Rugstad, O. Bentdal, G. Sodal, A. Hartmann, T. Leivestad, et al.
Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation.
Transplantation, 66 (1998), pp. 334-339
[72.]
E. Schutz, J. Gummert, V.W. Armstrong, F.W. Mohr, M. Oellerich.
Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation.
Eur J Clin Chem Clin Biochem, 34 (1996), pp. 199-205
[73.]
L. Lennard, J.A. Van Loon, R.M. Weinshilboum.
Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism.
Clin Pharmacol Ther, 46 (1989), pp. 149-154
[74.]
W.J. Sandborn, W.A. Faubion.
Clinical pharmacology of inflammatory bowel disease therapies.
Curr Gastroenterol Rep, 2 (2000), pp. 440-445
[75.]
C. Cuffari, M. Picco, S. Hunt, T. Bayless.
Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD.
Gastroenterology, 116 (1999), pp. A694
[76.]
M.C. Dubinsky, S. Lamothe, H.Y. Yang, S.R. Targan, D. Sinnett, Y. Theoret, et al.
Optimizing and individualizing 6-MP therapy in IBD: the role of 6-MP metabolite levels and TPMT genotyping.
Gastroenterology, 116 (1999), pp. A702
[77.]
P.W. Lowry, C.L. Franklin, A.L. Weaver.
Cross-sectional study of IBD patients taking azathioprine (AZA) or 6-mercaptopurine (6-MP): lack of correlation between disease activity and 6-thioguanine nucleotide (6-TGN) concentration.
Gastroenterology, 118 (2000), pp. A788
[78.]
P. Gupta, R. Gokhale, B. Kirsher.
6-mercaptopurine (6MP) metabolite levels in children with IBD: lack of correlation of 6-thioguanine (6TG) levels with clinical response.
Gastroenterology, 118 (2000), pp. 4202
[79.]
M.C. Dubinsky, P.V. Hassard, M.T. Abreu.
Thioguanine (6-TG): a therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine (6-MP).
Gastroenterology, 118 (2000), pp. A891
[80.]
E.S. Vesell.
Therapeutic lessons from pharmacogenetics.
Ann Intern Med, 126 (1997), pp. 653-655
[81.]
M.E. Jeurissen, A.M. Boerbooms, L.B. Van de Putte.
Pancytopenia related to azathioprine in rheumatoid arthritis.
Ann Rheum Dis, 47 (1988), pp. 503-505
[82.]
B.R. Bacon, W.H. Treuhaft, A.M. Goodman.
Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases.
Arch Intern Med, 141 (1981), pp. 223-226
[83.]
L. Lennard, J.S. Lilleyman.
Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.
Ther Drug Monit, 18 (1996), pp. 328-334
[84.]
A. Anstey, L. Lennard, S.C. Mayou, J.D. Kirby.
Pancytopenia related to azathioprine –an enzyme deficiency caused by a common genetic polymorphism: a review.
J R Soc Med, 85 (1992), pp. 752-756
[85.]
L. Lennard.
Therapeutic drug monitoring of antimetabolic cytotoxic drugs.
Br J Clin Pharmacol, 47 (1999), pp. 131-143
[86.]
R.M. Weinshilboum, S.L. Sladek.
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.
Am J Hum Genet, 32 (1980), pp. 651-662
[87.]
R.M. Weinshilboum, F.A. Raymond, P.A. Pazmino.
Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties.
Clin Chim Acta, 85 (1978), pp. 323-333
[88.]
E. Jacqz-Aigrain, E. Bessa, Y. Medard, Y. Mircheva, E. Vilmer.
Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.
Br J Clin Pharmacol, 38 (1994), pp. 1-8
[89.]
C.R. Yates, E.Y. Krynetski, T. Loennechen, M.Y. Fessing, H.L. Tai, C.H. Pui, et al.
Molecular diagnosis of thiopurine Smethyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.
Ann Intern Med, 126 (1997), pp. 608-614
[90.]
D. Otterness, C. Szumlanski, L. Lennard, B. Klemetsdal, J. Aarbakke, J.O. Park-Hah, et al.
Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms.
Clin Pharmacol Ther, 62 (1997), pp. 60-73
[91.]
A.M. Rossi, M. Bianchi, C. Guarnieri, R. Barale, G.M. Pacifici.
Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects.
Eur J Clin Pharmacol, 57 (2001), pp. 51-54
[92.]
M.V. Relling, M.L. Hancock, G.K. Rivera, J.T. Sandlund, R.C. Ribeiro, E.Y. Krynetski, et al.
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
J Natl Cancer Inst, 91 (1999), pp. 2001-2008
[93.]
J.F. Colombel, N. Ferrari, H. Debuysere, P. Marteau, J.P. Gendre, B. Bonaz, et al.
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.
Gastroenterology, 118 (2000), pp. 1025-1030
[94.]
A.J. Black, H.L. McLeod, H.A. Capell, R.H. Powrie, L.K. Matowe, S.C. Pritchard, et al.
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.
Ann Intern Med, 129 (1998), pp. 716-718
[95.]
J.L. Snow, L.E. Gibson.
The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients.
Arch Dermatol, 131 (1995), pp. 193-197
[96.]
S.M. Tavadia, P.R. Mydlarski, M.D. Reis, N. Mittmann, P.H. Pinkerton, N. Shear, et al.
Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case.
J Am Acad Dermatol, 42 (2000), pp. 628-632
[97.]
H. Corominas, M. Doménech, D. González-Juan, B. González-Suárez, C. Díaz, J. Pujol, et al.
Aplasia medular tras administración de azatioprina: papel del polimorfismo genético de la tiopurina metiltransferasa.
Med Clin (Barc), 115 (2000), pp. 299-301
[98.]
W.E. Evans, Y.Y. Hon, L. Bomgaars, S. Coutre, M. Holdsworth, R. Janco, et al.
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
J Clin Oncol, 19 (2001), pp. 2293-2301
[99.]
S. Ishioka, K. Hiyama, H. Sato, Y. Yamanishi, H.L. McLeod, K. Kumagai, et al.
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese.
Intern Med, 38 (1999), pp. 944-947
[100.]
J.B. Andersen, C. Szumlanski, R.M. Weinshilboum, K. Schmiegelow.
Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.
Acta Paediatr, 87 (1998), pp. 108-111
[101.]
G. Leipold, E. Schutz, J.P. Haas, M. Oellerich.
Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis.
Arthritis Rheum, 40 (1997), pp. 1896-1898
[102.]
J.F. Gummert, E. Schutz, M. Oellerich, F.W. Mohr, H. Dalichau.
Monitoring of TPMT in heart transplant recipients under immunosuppressive therapy with azathioprine.
Artif Organs, 19 (1995), pp. 918-920
[103.]
Z. Ben Ari, A. Mehta, L. Lennard, A.K. Burroughs.
Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.
J Hepatol, 23 (1995), pp. 351-354
[104.]
P.J. Kerstens, J.N. Stolk, R.A. De Abreu, L.H. Lambooy, L.B. Van de Putte, A.A. Boerbooms.
Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis.
Arthritis Rheum, 38 (1995), pp. 142-145
[105.]
P.R. Chocair, J.A. Duley, H.A. Simmonds, J.S. Cameron.
The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients.
Transplantation, 53 (1992), pp. 1051-1056
[106.]
M.A. Naughton, E. Battaglia, S. O'Brien, M.J. Walport, M. Botto.
Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine.
Rheumatology (Oxford), 38 (1999), pp. 640-644
[107.]
J.N. Stolk, A.M. Boerbooms, R.A. de Abreu, D.G. de Koning, H.J. van Beusekom, W.H. Muller, et al.
Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis.
Arthritis Rheum, 41 (1998), pp. 1858-1866
[108.]
W.E. Evans, M. Horner, Y.Q. Chu, D. Kalwinsky, W.M. Roberts.
Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
J Pediatr, 119 (1991), pp. 985-989
[109.]
L. Lennard, I.J. Lewis, M. Michelagnoli, J.S. Lilleyman.
Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
Med Pediatr Oncol, 29 (1997), pp. 252-255
[110.]
W.J. Sandborn, O.E. Van, B.J. Zins, W.J. Tremaine, D.C. Mays, J.J. Lipsky.
An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease.
Gastroenterology, 109 (1995), pp. 1808-1817
[111.]
D.H. Casson, S.E. Davies, M.A. Thomson, A. Lewis, J.A. Walker-Smith, S.H. Murch.
Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease.
Aliment Pharmacol Ther, 13 (1999), pp. 891-895
[112.]
P.S. Kim, J. Zlatanic, B.I. Korelitz, G.W. Gleim.
Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
Am J Gastroenterol, 94 (1999), pp. 3254-3257
[113.]
C.J. Haber, S.J. Meltzer, D.H. Present, B.I. Korelitz.
Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease.
Gastroenterology, 91 (1986), pp. 982-986
[114.]
J. Cox, T.K. Daneshmend, C.J. Hawkey, R.F. Logan, R.P. Walt.
Devastating diarrhoea caused by azathioprine: management difficulty in inflammatory bowel disease.
Gut, 29 (1988), pp. 686-688
[115.]
D.H. Present, S.J. Meltzer, M.P. Krumholz, A. Wolke, B.I. Korelitz.
6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity.
Ann Intern Med, 111 (1989), pp. 641-649
[116.]
G.C. Actis, F. Bresso, M. Astegiano, B. Demarchi, N. Sapone, C. Boscaglia, et al.
Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis.
Aliment Pharmacol Ther, 15 (2001), pp. 1307-1311
[117.]
I. Lorenzen, C. Brun, A. Videbaek.
Treatment of immunologic diseases with cytostatics.
Acta Med Scand, 185 (1969), pp. 501-506
[118.]
E. Ginzler, E. Sharon, H. Diamond, D. Kaplan.
Long-term maintenance therapy with azathioprine in systemic lupus erythematosus.
Arthritis Rheum, 18 (1975), pp. 27-34
[119.]
H.G. Mertens, G. Hertel, P. Reuther, K. Ricker.
Effect of immunosuppressive drugs (azathioprine).
Ann N Y Acad Sci, 377 (1981), pp. 691-699
[120.]
W.R. Connell, M.A. Kamm, J.K. Ritchie, J.E. Lennard-Jones.
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.
Gut, 34 (1993), pp. 1081-1085
[121.]
J. Shorey, S. Schenker, W.N. Suki, B. Combes.
Hepatotoxicity of mercaptopurine.
Arch Intern Med, 122 (1968), pp. 54-58
[122.]
E.F. Posthuma, R.G. Westendorp, A. Van der Sluys Veer, J.C. Kluin-Nelemans, P.M. Kluin, C.B. Lamers.
Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine.
Gut, 36 (1995), pp. 311-313
[123.]
J. Vassallo, A.C. Galizia, P. Cuschieri.
Mixed pulmonary infection with Nocardia, Candida, methicillin-resistant Staphylococcus aureus, and group D Streptococcus species.
Postgrad Med J, 72 (1996), pp. 680-681
[124.]
I.A. Mouzas, A.J. Greenstein, E. Giannadaki, S. Balasubramanian, O.N. Manousos, D.B. Sachar.
Management of varicella infection during the course of inflammatory bowel disease.
Am J Gastroenterol, 92 (1997), pp. 1534-1537
[125.]
M. Khatchatourian, T.L. Seaton.
An unusual complication of immunosuppressive therapy in inflammatory bowel disease.
Am J Gastroenterol, 92 (1997), pp. 1558-1560
[126.]
B.I. Korelitz, S.R. Fuller, J.I. Warman, M.D. Goldberg.
Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease.
Am J Gastroenterol, 94 (1999), pp. 424-426
[127.]
A. Garrido Serrano, F. Pérez Martin, F.J. Guerrero Igea, J. Galbarro Muñoz, S. Palomo Gil.
Fatal infectious mononucleosis during azathioprine treatment in Crohn's disease.
Gastroenterol Hepatol, 23 (2000), pp. 7-8
[128.]
F. Castiglione, G. Del Vecchio Blanco, A. Rispo, A. Cozzolino, E. Di Girolamo, D. Cappuccio, et al.
Hepatitis related to cytomegalovirus infection in two patients with Crohn's disease treated with azathioprine.
Dig Liver Dis, 32 (2000), pp. 626-629
[129.]
J.R. Boulton-Jones, K. Pritchard, A.A. Mahmoud.
The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy.
Aliment Pharmacol Ther, 14 (2000), pp. 1561-1565
[130.]
D.G. Bowen, W.S. Selby.
Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine.
Dig Dis Sci, 45 (2000), pp. 1810-1813
[131.]
B.I. Korelitz, J. Zlatanic, F. Goel, S. Fuller.
Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease.
J Clin Gastroenterol, 28 (1999), pp. 341-344
[132.]
C.H. Floren, B. Ahren, M. Bengtsson, J. Bartosik, K. Obrant.
Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine.
J Intern Med, 243 (1998), pp. 123-126
[133.]
H.A. Kader, W.J. Wenner Jr, G.W. Telega, E.S. Maller, R.N. Baldassano.
Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease.
J Clin Gastroenterol, 30 (2000), pp. 409-413
[134.]
E.M. Alstead, J.K. Ritchie, J.E. Lennard-Jones, M.J. Farthing, M.L. Clark.
Safety of azathioprine in pregnancy in inflammatory bowel disease.
Gastroenterology, 99 (1990), pp. 443-446
[135.]
S. Saarikoski, M. Seppala.
Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus.
Am J Obstet Gynecol, 115 (1973), pp. 1100-1106
[136.]
A. Francella, A. Dayan, P. Rubin.
6-mercaptopurine (6-MP) is safe therapy for child bearing patients with inflammatory bowel diseasa (IBD): a case controlled study.
Gastroenterology, 110 (1996), pp. A909
[137.]
N. Muirhead, A.R. Sabharwal, M.J. Rieder, A.I. Lazarovits, D.J. Hollomby.
The outcome of pregnancy following renal transplantation –the experience of a single center.
Transplantation, 54 (1992), pp. 429-432
[138.]
N.M. Janssen, M.S. Genta.
The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation.
Arch Intern Med, 160 (2000), pp. 610
[139.]
R.O. Rajapakse, B.I. Korelitz, J. Zlatanic, P.J. Baiocco, G.W. Gleim.
Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease.
Am J Gastroenterol, 95 (2000), pp. 684-688
[140.]
S.V. Kane.
What's good for the goose should be good for the gander –6-MP use in fathers with inflammatory bowel disease.
Am J Gastroenterol, 95 (2000), pp. 581-582
[141.]
A.J. Greenstein, G.E. Mullin, J.A. Strauchen, T. Heimann, H.D. Janowitz, A.H. Aufses Jr, et al.
Lymphoma in inflammatory bowel disease.
Cancer, 69 (1992), pp. 1119-1123
[142.]
A. Gelb, R. Zalusky.
The use of azathiaprine and 6-mercaptopurine (6-MP) as immunosuppressive therapy in inflammatory bowel disease and its role in the etiology of lymphocytic lymphoma.
Am J Gastroenterol, 78 (1983), pp. 316
[143.]
L. Larvol, J.C. Soule, A. Le Tourneau.
Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease.
N Engl J Med, 331 (1994), pp. 883-884
[144.]
M. Lemann, P. Bonhomme, A. Bitoun, B. Messing, R. Modigliani, J.C. Rambaud.
Treatment of Crohn's disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases.
Gastroenterol Clin Biol, 14 (1990), pp. 548-554
[145.]
B.I. Korelitz, F.J. Mirsky, M.R. Fleisher, J.I. Warman, N. Wisch, G.W. Gleim.
Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Am J Gastroenterol, 94 (1999), pp. 3248-3253
[146.]
S.G. Meuwissen, K. Ewe, M.A. Gassull, K. Geboes, D. Jewell, F. Pallone, et al.
IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases.
Eur J Gastroenterol Hepatol, 12 (2000), pp. 13-18
[147.]
C.W. Tan, G.E. Wilson, J.M. Howat, D.R. Shreeve.
Rectal lymphoma in ulcerative colitis treated with azathioprine.
Eur J Gastroenterol Hepatol, 13 (2001), pp. 898-992
[148.]
W.R. Connell, M.A. Kamm, M. Dickson, A.M. Balkwill, J.K. Ritchie, J.E. Lennard-Jones.
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.
Lancet, 343 (1994), pp. 1249-1252
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
